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ABSTRACT - Introduction: Use of tranexamic acid (TXA) in trauma has been the subject of growing 
interest by researchers and health professionals. However, there are still several open questions 
regarding its use. In some aspects medical literature is controversial. The points of disagreement 
among experts include questions such as: Which patients should receive TXA in trauma? Should 
treatment be performed in the pre-hospital environment? Is there any need for laboratory 
parameters before starting TXA treatment? What is the drug safety profile? The main issue on 
which there is still no basis in literature is: What is the indication  for treatment within massive 
transfusion protocols? Objective: Answer the questions proposed based on critical evaluation 
of the evidence gathered so far and carry out a study of cost-effectiveness of TXA use in trauma 
adapted to the Brazilian reality. Methods: A literature review was performed through searching 
Pubmed.com, Embase and Cab Abstract by headings “tranexamic AND trauma”, in all languages, 
yielding 426 articles. Manuscripts reporting on TXA utilization for elective procedures were 
excluded, remaining 79 articles. Fifty-five articles were selected, and critically evaluated in order 
to answer study questions. The evaluation of cost effectiveness was performed using CRASH-2 
trial data and Brazilian official population data. Results: TXA is effective and efficient, and should 
be  administered to a wide range of patients, including those with indication evaluated in 
research protocols and  current indication criteria for TXA should be expanded. As for the cost-
effectiveness, the TXA proved to be cost-effective with an average cost of R$ 61.35 (currently 
US$16) per year of life saved. Conclusion: The use of TXA in trauma setting seems to be effective, 
efficient and cost-effective in the various groups of polytrauma patients. Its use in massive 
transfusion protocols should be the subject of further investigations.
RESUMO - Introdução: O uso do ácido tranexâmico (TXA) no trauma tem sido alvo de interesse 
crescente por parte de pesquisadores e profissionais de saúde. No entanto, seus benefícios 
ainda não foram completamente definidos. Os pontos de divergência entre especialistas incluem 
questões como: quais pacientes devem receber TXA no trauma? O tratamento deve ser realizado 
em ambiente pré-hospitalar? Há necessidade de exames laboratoriais para indicar o tratamento? 
Qual o perfil de segurança da droga? A principal questão para a qual ainda não existe qualquer 
embasamento na literatura é: qual a indicação do tratamento dentro de protocolos de transfusão 
maciça? Objetivo: Responder às questões propostas, com base em avaliação crítica da evidência 
reunida até o momento e realizar estudo de custo-efetividade do uso do TXA no trauma 
adaptado à realidade brasileira. Métodos: Foi realizada revisão da literatura através de estratégia 
de busca: PubMed.com, Embase e no Cab Abstract pelos descritores “tranexamic AND trauma”, 
em todos idiomas, resultando em 426 artigos. Foram excluídos aqueles relativos às operações 
eletivas, restando 79 artigos. Cinquenta e cinco foram selecionados e avaliados criticamente 
com vistas a responder às questões em estudo. A avaliação de custo-efetividade foi realizada 
utilizando dados do estudo CRASH-2 e populacionais oficiais brasileiros. Resultados: Através da 
análise da evidência disponível chegou-se à conclusão de que o ácido tranexâmico é tratamento 
eficaz e efetivo, devendo ser administrado à ampla gama de pacientes, incluindo todos aqueles 
com indicação já avaliada nos protocolos de pesquisa publicados e provavelmente devam-se 
expandir os critérios de indicação. Quanto à avaliação de custo-efetividade, o TXA mostrou-se 
bastante custo-eficaz com gasto médio de R$ 61,35 por ano de vida salvo. Conclusão: O uso 
do ácido tranexâmico no trauma parece ser eficaz, efetivo e custo-eficaz nos diversos grupos de 
pacientes politraumatizados. Seu uso em protocolos de transfusão maciça ainda deve ser objeto 
de futuras investigações. 
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INTRODUCTION
Tranexamic acid (TXA) is a synthetic analogue of the amino acid lysine, discovered in the laboratory in 1962. TXA has low commercial cost, which has favored its routine use for patients presenting with metrorrhagia and for 
bleeding prevention in patients with hereditary bleeding disorders submitted to dental 
extraction2. More recently, TXA use has been expanded to patients undergoing elective 
surgery, showing to reduce the needs for blood transfusion7.
TXA acts by reversibly binding to lysine receptor sites on plasminogen, thus 
preventing it to bind to the tissue plasminogen activator (tPA). Once this binding is 
prevented, plasmin will not be formed, avoiding fibrinolysis1.
Randomized controlled trials, cohort studies and meta-analyzes were performed 
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to evaluate and measure the potential effects of TXA utilization 
in trauma patients3,5,20,23.
Because of the universal distribution of trauma and its 
concentration in low and middle per capita income countries, 
it becomes important to evaluate cost-effectiveness of TXA 
in this scenario. Studies evaluating cost-effectiveness of TXA 
in different Countries have been published. However there 
are no prior studies evaluating the Brazilian reality with its 
peculiarities that hinder its comparison to other countries of 
lower income per capita6.
This study aimed to review the accumulated knowledge 
in the use of TXA and respond to issues that are relevant to 
clinical practice. In addition it is intended to make an analysis of 
the cost effectiveness of TXA use specifically to Brazilian reality.
METHODS
Search strategy: PubMed, Medline, Embase and Cab 
Abstract by the terms “tranexamic AND trauma” in all languages, 
resulting in 426 articles. Those related to elective surgery were 
excluded, remaining 79 articles. After excluding those with 
irrelevant content for the purpose of this study, 55 articles 
have remained. Among these, there were seven original articles 
reporting on intervention studies, two Cochrane meta-analysis, 
an one cost-effectiveness study, six review articles and six 
subgroup analyzes from previous studies.
Evaluation of cost effectiveness of TXA was performed 
by calculating the incremental cost of treatment divided by 
the number of years of life gained with the intervention. The 
determination of the incremental cost of treatment, i.e., the extra 
amount to be spent on the implementation of the treatment 
compared to standard treatment (without use of TXA) was 
performed  taking into account the estimated costs for the 
treatment of patients with TXA in the dose recommended by 
the study “Effects of tranexamic acid in death”, vascular occlusive 
events, and blood transfusion in trauma Patients with significant 
hemorrhage (CRASH-2)5, i.e. 1 g EV dose plus 1 g IV after eight 
hours. The spent considered standard treatment for application 
of TXA was eight 250mg vials of TXA, two 40X12 mm needles, 
two 20 ml syringes, one regular infusion set, one micro i.e. 
infusion set and two 100 ml bottles of saline. Unlike what was 
done in previous studies incremental spending on labor on 
TXA infusion was not considered because the Brazilian health 
public system (SUS), as it is organized, allows small procedures 
to be added to the care practice without requiring to hire new 
staff. To determine the incremental cost of treatment, budget 
was performed by utilizing TXA vials obtained from leading 
manufacturers and laboratories. Other materials needed for 
administration of TXA had their values  determined by consulting 
the lower values  of online auction. To determine the average 
incremental cost of treatment simple arithmetic average of the 
highest and lowest value found was performed.
As for calculating the number of years of life gained with 
the treatment the following equation was utilized:
Number of years of life gained = (average Brazilian life expectancy 
- mean age of the CRASH-2 patients) / (NNT from CRASH-2)
In this equation, NNT is the number of patients to be 
treated to prevent one death in CRASH-2 study. In other words, 
NNT is the inverse of the absolute risk reduction. Having the 
number of life years gained and average incremental cost of 
treatment, we can directly estimate the cost-effectiveness using 
the formula below:
Cost-effectiveness = (average price of treatment) / number 
of years life gained)
in which the cost-effectiveness is given in R$ (Brazilian 
currency) per life year gained.
This formula was utilized instead of a parametric function 
Gompertz used in other cost-effectiveness study published on 
the subject6 because of its simplicity, for disregard of computing 
resources for its calculation and because it fits well to reality. 
In addition to that, almost all of the deaths related to trauma 
occurring in the CRASH-2 study follow-up period and that 
the group of patients included in this study should not differ 
statistically with respect to age of patients seen in Brazilian 
trauma centers. The NNT data comes from the CRASH-2 study, 
which are the most reliable. To determine the expected average 
Brazilian life, used in conjunction with the NNT for calculating 
the number of years of life gained with treatment, 2014 official 
data were used.
RESULTS
Literature review
According to meta-analysis there is no statistically significant 
relationship between use of TXA and mortality reduction 
in elective surgeries. However, the low prevalence of death 
secondary to bleeding in elective surgeries may have contributed 
to make the magnitude of a possible benefit not possible to 
estimate due to the statistical power of the studies3. However, 
this same review showed benefits in outcomes such as need 
for blood transfusion (reduced by one third), volume of blood 
transfusion (reduced by one pack or red cells concentrate per 
patient) and need for surgical reoperation due to bleeding 
(halved)3. In polytrauma victims, due to unscheduled nature 
of tissue damage, there is a greater tendency for bleeding 
secondary to small vessel trauma if compared to the controlled 
damage generated by elective surgery. Thus, it is likely that, as 
has been proven in elective surgeries, there may be benefit in 
the administration of tranexamic acid. Additionally, since the 
death outcome secondary to bleeding is much more common 
in trauma patients than in patients undergoing elective surgical 
procedures, it was even possible to assume that the benefit 
not observed mortality in the meta-analysis for elective surgery 
would be obtained for trauma patients.
An additional meta-analysis in the context of antifibrinolytic 
use in trauma was conducted20. The evidence gathered at the 
time was insufficient to prove the effectiveness of antifibrinolytic 
use due to the small amount of existing studies and the 
small number of patients evaluated by them. In 2010, a large 
randomized clinical trial (RCT), double-blind, placebo-controlled, 
the CRASH-2 study evaluated 20,211 trauma victims. This study 
was able to demonstrate the benefits of the use of TXA on 
overall mortality and also for mortality related to bleeding in 
the trauma setting. It was thus confirmed the theoretical benefit 
proposed above. However, surprisingly, this study showed no 
decrease in the need or the amount of blood products for 
the care of patients5. After this study was published, a new 
meta-analysis was performed20. After excluding inappropriate 
studies or studies with unacceptable biases and also by adding 
patients of CRASH-2 this new meta-analysis revealed different 
conclusions than those of from the 2008 review20. Due to the 
huge difference in sample space between the two studies 
eligible for this review (77 against 20211) the data produced 
resulted almost identical to the CRASH-25,20. Soon after, a 
retrospective observational study evaluating the use of TXA 
in military environment, the military Application of Tranexamic 
Acid in Trauma Emergency Resuscitation (MATTERs, 2012) was 
published14. Subgroup analysis of this study compared use 
of TXA and use of TXA associated with cryoprecipitate and 
showed encouraging results, suggesting additional benefit 
with combined use of cryoprecipitate and TXA15. However, 
because it is not an ECR and only included patients with serious 
injuries in military environment, such data are not subject to 
comparison with those generated by the aforementioned 
studies. There are no randomized trials evaluating the use of 
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5.53 to 6.04 (p=0.01), and the number of patients with systolic 
blood pressure less than 90 mmHg, 22.8% vs. 13.8% (p=0.003)15. 
The group receiving TXA was sicker, as widely documented. 
Although it makes even more robust the reduction in mortality 
obtained by the use of TXA, it casts doubt on the increase in 
thromboembolic events observed in the treatment group. 
This increase could be due to potential effect of TXA or could 
simply derive from the greater severity of the patients in this 
group or even could derive from the combination of these 
two causes. Reinforcing this point of view, adjusting the risk of 
patients by severity, the thromboembolic risk ratio potentially 
could turn to not be statistically significant18. Analyzing the two 
newly exposed factors, it is clear that both the evidence of the 
CRASH-2, contrary to the existence of a prothrombotic effect5, 
and the evidence of MATTERs favorable to the existence of this 
effect may not seem reliable15.
Only one study was designed with the main objective to 
assess thromboembolic events in trauma patients treated with 
TXA. This is an observational study that evaluated 115 patients 
at high risk for such events. This study found no difference in the 
occurrence of thromboembolic events among patients receiving 
TXA vs. those not receiving the drug (p=0.788)25. Although it 
comes from an observational study, it apparently presents with 
appropriate design and brings reliable data to determine the 
safety of the drug. Finally, we should remember that the CRASH-
2 study showed small but statistically significant reduction in 
the incidence of acute myocardial infarction in the treatment 
group5. This benefit may be due to lower oxygen consumption 
by the myocardium in patients whose bleeding was reduced by 
the action of the drug9. Thus, the accumulated evidence to date 
points to the safety of treatment with TXA; however, there is 
still need for further RCTs designed to evaluate the occurrence 
of thromboembolic events as the primary outcome and the 
potential reduction in the occurrence of myocardial infarction 
or other ischemic events.
Criteria for therapy with TXA use
Both the CRASH-2 study and the MATTERs study utilized 
clinical parameters to indicate the treatment or inclusion in the 
study5,14. Criticism was directed to the authors of the former 
study, pointing out that laboratory parameters should better 
evaluate patients with hyperfibrinolysis and thus they should 
be better indicators of which patients would benefit most from 
the treatment17. The authors of the present study disagree with 
this point of view, since the decision making in trauma cannot 
always expect results of laboratory tests, which are not always 
readily available. It is considered one of the strengths of the 
CRASH-2, the clinical scenario in which it was done. Regarding 
its multicentric nature and the prevalence of low and middle 
per capita income countries among the participants, the study 
accurately portraits the reality where victims of trauma are 
concentrated around the world. The disadvantage of including 
patients who are not at hyperfibrinolysis state in the study is 
to reduce the magnitude of benefit. If, even with this possible 
reduction of the magnitude of this benefit was even gaugeable 
and significant, the greater should be the benefit brought to 
patients for treatment. Furthermore, there is no diagnostic test 
specific and 100% sensitive. Thus, expecting the results from 
laboratory tests to start TXA therapy, could deny potentially life-
saving therapeutic interventions to patients who could benefits 
from these. On the other hand, when a treatment of low cost and 
high safety profile as TXA is overprescribed, the risks are is likely 
to be outweighed by the benefits. Even though the potential 
benefits of thromboelastography and thromboelastometry 
cannot be denied17, only it is argued here that the data from 
these methods will find their best application for the indication 
of high cost or low therapeutic index treatments such as the use 
of blood derivatives. In summary, the use of clinical parameters 
for inclusion of patients in the study, namely the use of clinical 
criteria for treatment indication, criticized by some researchers, 
TXA in the trauma setting.
There remain many questions to be answered about the 
use of TXA in the trauma setting. No information is available 
on the efficacy and effectiveness of the association of TXA and 
blood products or its use in massive transfusion protocols. There 
is no evidence from controlled studies of the possible synergistic 
effect observed between TXA and cryoprecipitate evaluated 
by the MATTERs study; there is no data on the use of TXA in 
patients undergoing damage control surgery. Furthermore, 
there are no specific data specifically evaluating subgroups 
of patients suffering from penetrating or blunt injury. The 
mechanism by which this drug acts in trauma, especially with 
regard to its anti-inflammatory effect remains uncertain2. Also, 
the efficiency and effectiveness of TXA as a drug for prehospital 
use has not been established yet.
Key issues
Mortality prevention: When should TXA be indicated?
The largest benefit in mortality prevention with the use 
of TXA is observed in patients with established coagulopathy 
and severe trauma5,8,12. This  prompted researchers to question 
whether indication of TXA should or not be restricted in this 
subgroup of patients. The authors of this study agree with 
Roberts19,21 when he advocates the use of TXA in all trauma 
patients with bleeding or risk of bleeding18. Since differences 
in systolic blood pressure of patients does not generate 
statistical difference in mortality secondary to hemorrhage 
(main mechanism of action of treatment, p=0.33)21 remains clear 
that this is effective in all degrees of shock, i.e., their biological 
effect is exerted almost uniformly in all patients regardless of 
their systolic pressure. Thus, the difference in mortality from 
all causes identified among the sickest patients seems to be 
a mere statistical artifact secondary to higher death rate in 
the group of critically ill patients, it seems logical to indicate 
treatment in all groups of patients suffering shock, since this 
can prevent the less sick patients to evolve to higher degrees 
of shock, like III or IV and, only then, be consider eligible for 
the use of TXA. This strategy seems more appropriate since 
there is a clear relationship between early use of TXA and better 
clinical outcomes5.
Potential increase in the risk of thromboembolic events
Although the CRASH-2 study did not report statistically 
significant differences with regards to thromboembolic events 
in the intervention and control5 groups, there is biological 
plausibility for an increase in thromboembolic events in 
patients being treated with TXA. As occurred with the use 
of aprotinin, a drug structurally similar to TXA, increased risk 
of thromboembolic events may appear in later studies13. The 
results of the MATTERs study showed increased occurrence of 
these events for patients receiving TXA vs. controls: 0.3% of 
pulmonary thromboembolism in the control group vs. 2.7% 
(p=0.01) in TXA group, and 0.2% of deep venous thrombosis 
in the TXA group vs. 2.4% (p=0.01) in controls for deep venous 
thrombosis15. There are two key issues to comment on disparity 
of the results of between these two studies. As for CRASH-2 
data, since the most 274 centers involved in the study were 
located in low- and middle - income per capita5 and thus 
with less access to diagnostic methods, it is possible to have 
occurred under-reporting of events. This potentially could have 
masked a possible increased risk of thromboembolic events. 
Moreover, patients enrolled in MATTERs were not randomized, 
some patients being relocated to intervention or to placebo 
groups14 during the study. There was clearly a sicker group 
of patients who received TXA compared to the group that 
received no intervention. It may be seen by comparing the 
number of patients with Glasgow Coma Score ≤8, equal to 
63.3% in the intervention group versus 35.6% in the control 
group (p<0.001), the ISS (injury severity score) average with 
25.2 versus 22.5 (p<0.001)15, the RTS (revised trauma score) 
reVieW Article 
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seem least one study design defect than an additional factor 
that increases the external validity of the study.
Protocols of massive transfusion
There are no studies directly evaluating the use of TXA 
in massive transfusion protocols. The only data available 
related to the subject comes from subgroup analysis of the 
MATTERs study15. In the study, the use of TXA in combination 
with cryoprecipitate showed a reduction in mortality when 
compared to the individual use of each and to the control 
group. It was also demonstrated an independent effect for each 
intervention. Data obtained through logistic regression showed 
that the odds ratio  towards death for the treatment group 
receiving isolate cryoprecipitate  as compared to the absence 
of treatment was 0.61 (p=0.02), being 0.61 (p=0.01) for TXA 
and 0.38 (p<0.01) for the combination of both15. This profile 
raised the possibility of synergism between cryoprecipitate 
and TXA, which was tested by the same researchers, without 
obtaining the statistical significance achieved in this assessment 
of synergism (p=0,21). Although the existence of interaction 
was not proved, it cannot be rejected, raising the need for 
further studies in this subject.
Prehospital Care
A recent study in the prehospital care with medical 
evacuation by helicopter was published in 201326. Inclusion 
criteria for this study were: patients older than 16 years of 
age, heart rate of more than 110 beats per minute and systolic 
blood pressure of less than 90 mmHg (very similar criteria to 
the ones from CRASH-2 study)5,26. The intervention included 
TXA administration to all patients during transport, associated 
to treatment with permissive hypotension in those with injuries 
in the chest and abdomen. This study evaluated 13 patients 
who were administered TXA in an average time of 32 min 
after the arrival of the team to the scene. As the mean time 
to response was reported as 33 min, it is concluded that TXA 
was administered on average 65 min after injury. The authors 
did not report any adverse effects related to intervention26.
A cohort reporting the use of TXA in the prehospital 
environment by Israeli defense forces also was published11. 
Forty cases were reported, in whom treatment was started 
as soon as possible without delay11. Inclusion criteria were: 
penetrating wound in the neck, chest, abdomen or pelvis 
or any penetrating or blunt injury accompanied by signs of 
shock. The authors defined shock as systolic pressure of less 
than 90 mmHg, heart rate above 100 beats per minute in two 
consecutive measurements, peripheral capillary refill greater 
than 2 s or altered level of consciousness not associated with 
blunt TBI11. Clearly the authors used much broader inclusion 
criteria than those adopted by the CRASH-25,11. There were no 
reports of adverse effects related to treatment, which increases 
the importance of the findings, since there were liberal criteria 
to indicate treatment in this study11. The authors emphasized 
the importance of the safety profile of TXA, since in their point 
of view, prehospital care teams tend to overprescribe drugs11.
From the data of both studies, which together totalized 
53 patients, it can be concluded that, although the published 
experience is still modest, it seems safe to use TXA in the 
prehospital environment. Note also that the average use time 
of the trauma was 65 min in the first study (no data concerning 
this second study), that is, the upper limit of subgroup analysis 
showed greater benefit in the CRASH-2. Similarly, recently 
published study reports on a series of 20 consecutive patients 
receiving TXA during prehospital aeromedical transports with 
no adverse effects16. Thus, due to the apparent lack of serious 
adverse effects and the superiority of the treatment provided in 
the first hour5, it seems  that the prehospital environment would 
be an appropriate setting for the use of TXA in trauma. With 
the publication of PATCH study more data should be available, 
helping to dissolve the still lingering doubts concerning the 
use of TXA in prehospital care.
Cost-effectiveness analysis of the use of TXA
The potential of avoiding a large number of deaths using 
the TXA has been identified by various researchers. Estimates 
based on CRASH-2 data and epidemiological information from 
the World Health Organization (WHO) come to point out the 
possibility of avoiding 128,000 of the 400,000 annual deaths 
that occur in bleeding trauma patients around the world22. 
Study evaluating the cost-effectiveness of the use of TXA in 
trauma, in three different scenarios, was conducted: England 
(high gross domestic product, GDP, per capita), India (middle 
GDP per capita) and Tanzania (low GDP per capita)6. However 
it does not seem possible to extrapolate these results to the 
Brazilian reality.
In order to clarify some of these questions, this study 
aims to make a cost-effectiveness evaluation of TXA use in 
trauma in Brazil.
To evaluate the price of TXA, a survey of prices of TXA 
provided by different laboratories, Pfizer (reference product) 
Nikkho (similar), Hipolabor (generic) and EMS (generic) was 
conducted. Evaluation of official data published online trading 
days from January 2013 to December 2014, for vials of 250 mg 
of TXA. Costs related to the other materials required for the 
administration of TXA described above were estimated through 
evaluating the results of official electronic auctions published 
between January 2013 and December 2014. For the study 
purposes only winning proposals for each one of the sessions 
were considered, as they represent the actual value paid in 
acquisitions made  by Brazilian public hospitals responsible for 
the care of most trauma patients in Brazilian public healthcare 
system. The calculated values  are shown in Table 1.
The 2014 official data estimates the Brazilian life expectancy 
at 74.9 years. Using the data above, the information of the 
CRASH-2 study and the formula presented in the section 
above, the following value were obtained: R$ 54.65 per life 
year gained using the lower available prices, and R$ 116.63 
using If the higher available prices resulting in an average of 
R$ 85.64. It is still possible to infer that the incremental cost of 
treatment with TXA to save a life ranges from R$ 2,202.29 to 
R$ 4,700.05, with an average of R$ 3,451.17. For comparison 
purposes, a study calculated the cost per year of life gained for 
$ 48 (international dollars) in Tanzania, $ 66 in India and $ 64 in 
the United Kingdom6. It may be highlighted that the data are 
from 2011 and the researchers used even older TXA quotations, 
with prices ranging between $ 2.57 and $ 45.67 for drug 2 g, 
very different from R$ 15.76 to R$ 48.00 practiced in Brazil.
TABLE 1 - Incremental cost of TXA treatment
Product Necessary amount Biggest price Lowest price Higher total price Lowest total price
Tranexamic acid 250mg/5 ml 8 vials R$ 6.00 R$ 1.97 R$ 48.00 R$ 15.76
Needle 40X12 mm, or similar 2 units R$ 0.14 R$ 0.08 R$ 0.28 R$ 0.16
Syringe 20 ml 2 units R$ 0.49 R$ 0.22 R$ 0.98 R$ 0.44
100 ml physiological saline 2 units R$ 1.36 R$ 0.89 R$ 2.72 R$ 1.78
Regular infusion set 1 unit R$ 1.17 R$ 0.67 R$ 1.17 R$ 0.67
Micro i.v. infusion set 1 unit R$ 17.00 R$ 14.06 R$ 17.00 R$ 14.06
Total expenditure - - - R$ 70.15 R$ 32.87
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CONCLUSION
The effectiveness of TXA in trauma seems well established 
(level of evidence A)5,20. The effect of the drug seems to extend to 
patients in military environment (level of evidence C)14. Although 
there are no studies that discriminate patients suffering from 
penetrating and blunt trauma, there seems to be an indication 
of the use of TXA in both groups (level of evidence A)5,20. Thus, 
the need for studies separating these two groups (penetrating 
vs. blunt trauma patients) is more important for epidemiological 
purposes than for driving clinical practice. There is evidence 
of the safety of the use of tranexamic acid in the prehospital 
setting (level of evidence C)11,26. The authors of this study believe 
that, since that there is enough evidence that the sooner TXA 
is used, the greater the benefit it provides, additional studies 
comparing the effectiveness of the drug administered in the 
prehospital environment with its use inside the hospital are 
not necessary5,24. However, for TXA inclusion in prehospital 
care protocols, new studies evaluating the safety of treatment 
would be warranted, since the available studies have included 
a small number of patients.
This study concluded that the use of TXA is highly cost-
effective, and the average cost for each year of life saved is 
estimated at R$ 61.35. This data highly justifies the adoption 
of TXA treatment for polytrauma protocols, following the 
prescription model used by the CRASH-2 teams, and entails 
conducting studies to assess the cost-effectiveness of protocols 
with even more comprehensive indication criteria for this drug.
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